Pfizer’s inclacumab did not beat a placebo in a Phase 3 test in sickle cell disease. The trial failure comes nearly a year after Pfizer voluntarily withdrew Oxbryta from the market after tests showed higher rates of complications and deaths for that sickle cell disease drug.
The post Pfizer Gets Another Dose of Disappointment as Sickle Cell Disease Drug Fails Pivotal Test appeared first on MedCity News.
